Status:
ACTIVE_NOT_RECRUITING
The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Sickle Cell Disease
Sickle B+ Thalassemia
Eligibility:
All Genders
12-21 years
Phase:
NA
Brief Summary
The primary objective of this study is to better understand factors contributing to variations in hydroxyurea (HU) adherence behavior in adolescents and young adults (AYA) with sickle cell disease (SC...
Detailed Description
Sickle cell disease is the most common genetic disorder in the US, affecting about 100,000 Americans, and about 1 in 400 African American live births, incurring annual health care costs of $335 millio...
Eligibility Criteria
Inclusion
- Age 12-21 years old
- Any sickle cell disease genotype
- On steady state of hydroxyurea for 2 months
- Own or have access to a smartphone
- Parents of patients that meet the eligibility criteria and are enrolled in the study will be included
Exclusion
- Patients with recent hospitalizations within the past 7 days
Key Trial Info
Start Date :
March 2 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2025
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04691323
Start Date
March 2 2021
End Date
December 1 2025
Last Update
December 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611